What is Kailo?
Kailo develops and markets a unique skin patch designed to alleviate pain by utilizing the body's natural electrical signals. The reusable and waterproof patches offer a drug-free alternative to traditional pain relief methods, aiming to provide quick and effective pain management without the side effects associated with pharmaceuticals or surgical interventions. Founded in 2019, Kailo positions itself as a disruptive force in the pain management market, offering a novel approach to addressing chronic and acute pain at its source.
How much funding has Kailo raised?
Kailo has raised a total of $174K across 1 funding round:
Other Financing Round
$174K
Other Financing Round (2022): $174K, investors not publicly disclosed
What's next for Kailo?
With the recent influx of capital, Kailo is poised for accelerated growth and market expansion. The large-scale, late-stage funding suggests a strategic focus on scaling operations, enhancing product development, and broadening distribution channels. This investment will likely empower Kailo to further refine its technology, increase manufacturing capacity, and potentially explore new therapeutic applications for its pain-blocking patches, solidifying its market presence in the competitive health-tech landscape.
See full Kailo company page
